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 Abstract 
Quantitative EEG (QEEG) has demonstrated good discriminative capacity for Dementia with Lewy 
Bodies (DLB) diagnosis as compared to Alzheimer’s Disease (AD) with a predictive value of 100% 
in a single cohort study. EEG in DLB was characterized by a dominant frequency (DF) in pre-alpha 
(5.5-7.5 Hz), theta, or delta bands and DF variability (DFV)> 1.2Hz, frequency prevalence (FP) 
pre-alpha in>40% and FP alpha in <32% of the epochs. 
To validate the aforementioned QEEG findings in independent cohorts of  clinically diagnosed 
DLB vs. AD patients, we analyzed EEG traces of 79 DLB and 133 AD patients (MMSE>20) 
collected from four European Centers.  
EEG traces from 19 scalp derivations were acquired as at least 10 min continuous signals and 
epoched in off-setting as series of 2 second-long epochs, subsequently processed by Fast Fourier 
Transform (frequency resolution 0.5 Hz).  
DLB patients showed EEG specific abnormalities in posterior derivations characterized by DF<8Hz 
FP pre-alpha >50%, FP alpha <25%. DFV was >0.5Hz.  AD patients displayed stable alpha DF, 
DFV<0.5Hz, FP pre-alpha<30%, and FP alpha>55%.   
DLB and AD differed for DF (p<10-6), DFV (p<0.05), FP pre-alpha (p<10-12) and FP alpha (p<10-
12).  Discriminant analysis detected specific cut-offs for every EEG mathematical descriptor; DF=8, 
DFV=2.2 Hz, FP pre-alpha=33%, FP alpha=41% for posterior derivations. 
If at least one of the cut-off values was met, the percentage of DLB and AD patients correctly 
classified was 90% and 64% respectively.  
The findings in this multicenter study support the validity of QEEG analysis as a tool for diagnosis 
in DLB patients. 
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Introduction 
 
Dementia with Lewy bodies (DLB) is the second most common cause of neurodegenerative 
dementia after Alzheimer’s disease (AD). Clinically, fluctuations in attention, visual hallucinations 
and extrapyramidal signs are cardinal features of DLB [1]. However, while neuropathological series 
have demonstrated high accuracy for the clinical diagnosis of AD [2], the accuracy of the clinical 
diagnosis of DLB is less satisfactory [3-4-5] because some of the core clinical features may not 
appear during the entire course of DLB [6] or may overlap with AD [7] . Thus, DLB tends to be 
underdiagnosed during life and often misdiagnosed as AD [8-9]. 
In addition, neuropathological findings show that AD and DLB share pathological features linked to 
amyloid deposition [1] and in vivo, molecular imaging studies, by amyloid positron emission 
tomography,  have confirmed a high prevalence of amyloid load in DLB patient populations [10]. 
It is important to differentiate between these diseases because DLB patients may be more sensitive 
to adverse effects of neuroleptics [11], may exhibit faster disease progression [12-13] and different 
response to acetylcholinesterase inhibitors [14,15] as compared to AD patients. 
The accurate differential diagnosis is also particularly relevant for the appropriate selection of 
patients for clinical trials.  
Great emphasis has recently been placed on methods evaluating the uptake of dopamine transporter 
in basal ganglia [16-17] and the  postganglionic sympathetic cardiac innervation[18]. These 
methods may improve clinical diagnostic accuracy of DLB, but there is a clear need of affordable 
non invasive markers to assist with accurate identification of this entity. 
Several studies from small cohorts suggested that EEG, analyzed in a variety of quantitative 
methods, is able to differentiate DLB from AD from  the very early disease stages with high 
specificity and sensitivity  [19-23]. These EEG alterations are highly correlated with the presence of 
fluctuating cognition [19-22].   
 
However, the aforementioned results were never replicated in larger cohorts, and this limited the 
generalizability of the conclusions.  
In a previous study [21], in an  attempt to differentiate DLB from AD patients on the basis of EEG 
characteristics, the highest statistical yields were obtained in the comparison of EEG variables 
measured on recordings from posterior derivations.  
AD patients presented with an EEG pattern characterized by alpha Dominant frequency (DF) 
prevalent in >55% of the EEG epochs and DF variability (DFV) <1.2 Hz. By contrast, DLB patients 
presented with derangement of EEG background activity, characterized by DF in bands lower than 
alpha (i.e. pre-alpha, theta, delta) with DFV >1.2 Hz,  pre-alpha frequency prevalence (FP) in >40% 
of the analyzed EEG epochs, and alpha FP in <32%. [21].  
In that study these features were able to fully differentiate between DLB and AD.  
The aim of the present study is to test the robustness of the previously developed EEG method of 
analysis in a multicenter setting without harmonization of the recordings.  
 
Materials and Methods 
Study design 
We analysed EEG traces of 79 patients with probable DLB [1] and 133 AD [24] from 4 different 
European Centers involved in a European multicenter DLB study (E-DLB): 1. Clinical Neurology 
Unit, Department of Neuroscience (DINOGMI), University of Genoa, Italy; 2. Memory clinic at 
Karolinska University Hospital, Huddinge, Sweden; 3. Institute of Neuroscience, Newcastle 
University, Newcastle upon Tyne, UK, 4. Department of Neurology, University Medical center 
Ljubljana, Slovenia. 
EEG recordings were obtained at each centers but analyzed centrally at the Department of 
Neuroscience, Imaging and Clinical Science, and Aging Research Centre, G. d’Annunzio 
University, Chieti, Italy.  
 
Diagnostic and clinical examination 
The diagnosis of DLB was made according to consensus criteria [1] by expert clinicians. 
Demographics and clinical procedures were not harmonized across centres, but at all centres the 
assessment included a detailed history with questions on previous diseases, drug history; and 
physical, neurological, and psychiatric examinations using standardized scales such as the motor 
subscale of the Unified Parkinson’s Disease Rating Scale and the Neuropsychiatric Inventory. 
Routine blood tests,  brain imaging and neuropsychological testing were  available, including 
assessment of REM sleep Behavior Disorder (RBD) [25]. Dopamine transporter SPECT scans 
((123) I-FP CIT SPECT) were performed in 38 (48%)  DLB patients, and 36 (95%) were rated as 
abnormal.  
Cognition was assessed using the Mini-Mental State Examination (MMSE) in 162 patients, or the 
Montreal Cognitive Assessment (MOCA) [26] in 60 patients. To be able to compare cognitive data, 
the MOCA score was converted to an equivalent MMSE score [27]. 
Local ethics committees at the individual centres approved the study. The patients signed an 
informed consent. 
Drug withdrawal and caffeine, nicotine and alcohol prohibition for at least 48 h prior to EEG 
recording were performed only in one Center. 
 
EEG recordings 
Quantitative EEGs were recorded with Ag/AgCl disk scalp electrodes from 19 scalp derivations 
placed according to the international 10-20 system, or with 128 scalp derivations and two additional 
electrodes placed on A1 and A2. Nineteen electrodes from Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, 
C4, Pz, P3, P4, T3, T4, T5, T6, O1, and O2 were considered for the analysis. EEG activity was 
analysed from single or multiple leads grouped to define the following scalp regions:  
anterior (Fz, Fp2, F7, Fp1, F3, F4, F8), posterior (Pz, P3, P4, O1, O2), temporal (T3, T4, T5, T6).    
Recordings were acquired continuously with subjects resting comfortably, with their eyes closed.  
  
EEG analysis 
EEG analyses were fully computerized and performed by experimenters blind to clinical diagnosis. 
Ninety blocks of artefact-free 2 second-long epochs appearing consecutively were selected off-line 
by visual inspection. Fast Fourier Transform (FFT) was applied on each epoch allowing a frequency 
resolution of 0.5 Hz. The obtained spectra values were then processed in order to compute a mean 
Power Spectrum (mPS) for each channel and expressed in µV2. The mPS was divided automatically 
into 4 frequency bands (3-4 Hz (delta), 4.5-5.5 Hz (theta), 6-7.5 Hz (pre-alpha), 8-12 Hz 
(alpha).[19] 
DF, i.e. the frequency where the spectral power value was greatest, was evaluated for each epoch. 
Single channel power spectra  were represented as Compressed Spectral Arrays (CSA) showing the 
sequences of absolute or relative power spectra values in each of the 90 analysed epochs.  
CSA is the epoch to epoch representation of FFT values, for each derivation. It shows peaks of 
amplitudes, corresponding to frequencies in a single epoch [28]. These peaks of amplitude could 
either be stable through time or change (i.e. different frequencies could have the highest amplitude 
through time). CSAs can be quantified by the following mathematical descriptors: a) DF, b) FP, i.e. 
percent of epochs where a dominant frequency band was observed (1-100%), c) DFV expressing 
the variability of DF across the 90 analyzed epochs [21].  
DF, DFV, FP were translated into five patterns of EEG activity. [21] 
The first pattern (CSA pattern 1, Stable alpha) was defined as characterized by all the following 
variables: dominant alpha in ≥60% of analyzed epochs (DF≥8 Hz, FP alpha ≥60%), DFV of alpha 
<0.6 Hz, mean DFV of all epochs <1.6 Hz.  
The second pattern (CSA pattern 2, unstable alpha with pre-alpha or theta/delta) consisted of all the 
following: dominant alpha in < 50% of epochs, dominant pre-alpha or theta (4.5-7.5 Hz) in ≥40% of 
epochs (FP pre-alpha >40%), mean DFV >2 Hz. . 
The third pattern (CSA pattern 3, stable pre-alpha) consisted of all the following: absence of alpha, 
stable pre-alpha, in ≥70% of  analyzed epochs,  DFV of the analyzed epochs <1.0 Hz.  
The fourth pattern (CSA pattern 4, unstable pre-alpha with theta/delta) consisted of: absence of 
alpha, dominant pre-alpha in <70% of analyzed epochs, dominant theta or delta in ≥40% of epochs, 
DFV >2.0 Hz.  
The last pattern (CSA pattern 5, unstable low frequency) consisted of absence of alpha/pre-alpha, 
delta dominant activity in > 2 subsequent epochs with DFV >4 Hz.  
In our previous study DLB patients showed a CSA pattern ranging from 2 to 5. AD patients had a 
CSA pattern 1. Thus, CSA patterns together with DF, DFV and FP from posterior derivations, 
which showed to have the highest statistical yields in the original study, were chosen as the primary 
outcome variables in the current study.  We also analysed CSA patterns with DF, DFV and FP 
recorded from anterior and temporal scalp derivations. 
 
Statistics 
Demographic and clinical differences between the two groups were assessed with the independent t 
test for continuous data that passed normality testing by Kolmogorov-Smirnov test and Levene’s 
test for equality of variances between groups. χ2 test was performed for categorical data. 
Independent t test was performed on  DF and DFV; analysis of variance (ANOVA) was performed 
on FP with group as categorical variable and FP as factor with four levels (FP in delta, theta, pre-
alpha and alpha band). Bonferroni test was used for post-hoc analysis and the level of statistical 
significance was set at 5% (p=0.05). We also performed a comparative analysis between all the 
EEG variables derived from the present study and those from the previous study. [21] 
A receiver operating characteristic (ROC) analysis was performed to determine new cut-off values 
for each EEG variable for single-patient classification and to estimate the best EEG variable to 
distinguish DLB from AD patients. Sensitivity and specificity were recalculated according to the 
new cut-off values.  
Discriminant analysis with stepwise statistics was also used to test the hypothesis that the EEG 
categorization could separate the two diagnostic groups. 
The analyses were also performed on DLB patients as compared to a numerically  equal group of 
AD patients matched with DLB patients for age, sex, education, MMSE and NPI total scores,  
randomly selected among the AD sample. 
 
Results 
The demographic and clinical characteristics of the total and centre-specific samples are shown 
respectively in Table 1 and in supplementary table 1. DLB group was younger (p=0.005) and 
included more males (p=0.01) compared to the AD group.   
As reported in Table 2, DLB and AD groups differed for DF, FP pre-alpha and FP alpha values in 
all the derivations explored (anterior, posterior and temporal) and for DFV values only in posterior 
derivations. 
Supplementary table 2 shows a comparative analysis between the aforementioned results and the 
corresponding results obtained in the original EEG study [21].  
Figure 1 shows FP values in delta, theta, pre-alpha and alpha band in anterior, temporal and 
posterior derivation for DLB and AD groups, and demonstrates that FP was highest in the pre-alpha 
band in DLB (p<10-12 in the comparison of DLB vs. AD in temporal and posterior derivations, 
p<10-9 in anterior derivations), whereas it was in the alpha band in AD (p<10-12 in the comparison 
of DLB vs. AD in temporal and posterior derivations, p<10-9 in anterior derivations) in all the 
derivations explored.  
ROC curve analysis on EEG variables showed the cut-off values reported in table 3, together with 
sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) of the 
EEG variables according to the reported cut-offs. The highest sensitivity was found in anterior 
derivations, whereas EEG variables values from posterior derivations were more specific.  
NPV values were higher than PPV for every EEG variable. 
Sensitivity and specificity of EEG variables were also tested with the cut-off values described in the 
previous EEG study [21]. Results are reported in supplementary table 3. In particular, cut-off for 
DFV was higher in the present study as compared to the previous study; FP pre-alpha was lower in 
the present study as compared to the previous study. Cut-off for CSA pattern was >2 in the present 
study while it was >1 in the previous study (table 3 and supplementary table 3). 
When combining all the EEG variables (DF<7.8 Hz, DFV>2.2 Hz, FP pre-alpha >32.7 Hz, FP alpha 
<40.7 Hz, CSA pattern >2) the sensitivity reached 90% and specificity reached 64% in the 
comparison between DLB and AD patients. 
Linear discriminant analysis applied on EEG variables indicated that the best discriminating 
variable between DLB and AD patients was FP in alpha band in all the derivations explored (Wilks' 
lambda= 0.75, 0.70 and 0.67; F=69, 89 and 104, respectively for anterior, temporal and posterior 
derivations; p<10-4 for all the derivations).  
Figure 2 shows ROC curves and Area Under Curve (AUC) values for each EEG variable from all 
the derivations.   
Among the 36 patients with positive (123) I-FP-CIT SPECT scan, only 3 could not be correctly 
classified as DLB according to EEG variables. On the other hand, the two patients with negative 
(123)I-FP-CIT SPECT  scan had an EEG pattern suggestive of a DLB diagnosis. By combining 
EEG with (123) I-FP-CIT SPECT scan, the percentage of DLB patients correctly classified reached 
100%. 
Statistical comparisons of EEG variables between DLB patients with positive (123) I-FP-CIT 
SPECT scan and AD patients showed significant differences and are reported in supplementary 
table 4. 
Statistical comparisons of EEG variables between DLB patients with positive (123) I-FP-CIT 
SPECT scan and DLB patients without (123) I-FP-CIT SPECT scan evaluation showed significant 
differences of DFV from posterior derivations (F(1,75)=4.1 p<0.05). Specifically DFV was greater 
in DLB with positive (123) I-FP-CIT SPECT scan (0.9±0.2 Hz) than DLB without (123) I-FP-CIT 
SPECT scan evaluation (0.4±0.1 Hz). No significant differences were found in the comparison of 
EEG variables from anterior and temporal derivations. 
Discriminant analysis on the EEG variables of the 36 patients with positive (123) I-FP-CIT SPECT 
scan vs. the 133 AD patients showed different cut-off values and higher sensitivity values as 
compared to discriminant analysis on the 79 DLB vs. the 133 AD patients. Results of the ROC 
analysis are reported in supplementary figure 1. Supplementary table 5 reports sensitivity, 
specificity, PPV and NPV values. 
Finally, to test for the use of drug treatment during the EEG recordings as a potential confounder,   
a statistical comparisons on EEG variables was performed between patients who were under 
treatment during EEG recording and patients where drug treatments were withdrawn before EEG. 
No significant differences were found in DLB group, whereas AD patients who underwent drug 
withdrawal before EEG had higher DF (p=0.001) and higher FP in alpha band (p<10-4) in posterior 
derivations as compared to AD patients who did not withdraw drug treatments. Significant results 
of the statistical comparisons are summarized in supplementary table 6. 
To verify whether our results were not biased by the possible contribution of age, sex, and 
education, we also performed the aforementioned analyses on DLB patients in comparison to a 
numerically equal number of AD patients matched for age, sex, education, MMSE and NPI total 
scores (supplementary table 7).  No differences were found between the analyses performed on the 
whole patient samples and the analyses performed on the matched samples. Results of the 
comparisons between the two matched groups are reported in supplementary tables 8 and 9. 
In the selected sample, when combining all the EEG variables (DF<7.8 Hz, DFV>2.3 Hz, FP pre-
alpha >31.6 Hz, FP alpha< 40.7 Hz, CSA pattern >1) the sensitivity reached 92% and specificity 
reached 61% in the comparison between DLB and AD patients. 
Linear discriminant analysis applied on EEG variables from the selected subgroup of patients 
indicated that the best discriminating variable between DLB and AD patients was FP in alpha band 
in all the derivations explored (as in the total sample) (Wilks' lambda= 0.77, 0.71 and 0.68; F=46, 
64 and 74, respectively for anterior, temporal and posterior derivations; p<10-4 for all the 
derivations).  
 
Discussion 
In this international multi-centre study based on routine clinical EEG recording, we demonstrate the 
discriminative power of automated EEG analysis to differentiate between DLB and AD. These 
results support our previous conclusions from a single-centre study suggesting that quantitative 
assessment of  DF, DFV and FP and qualitative assessment CSA specific patterns could accurately 
discriminate between DLB and AD [21].  
The present study confirms the best discriminative performance of the analysis of posterior 
derivations (table 2 and supplementary table 2).  
The inclusion of a larger population of AD and DLB patients from different European centers 
allowed us to better estimate cut-off and sensitivity values for EEG variables, reaching 90% of 
correct classification of DLB patients when combining all EEG variables.  
The sensitivity of (123) I-FP-CIT SPECT scan, which is considered the gold standard for the in 
vivo diagnosis of DLB, reached 95%.  By combining EEG with (123)I-FP-CIT SPECT  scan, the 
percentage of DLB patients correctly classified reached 100%. 
The combination of EEG variables reached high sensitivity (90%), but the specificity was low 
(64%) in comparison with AD patients. Previous findings [21] showed better specificity values due 
to the high percentage (100%) of AD patients which had CSA pattern 1 in posterior derivations, 
whereas in the present study only 60 % of AD patients had a CSA pattern 1 in posterior derivations 
(see supplementary table 2 for further details).  
A possible explanation for the low specificity of EEG results is that in the original study the patient 
selection method was particularly focused on the presence of fluctuating cognition: we 
operationally selected AD patients without any symptom suggestive of the presence of fluctuating 
cognition. All AD patients had a score 0 at the CAF questionnaire and the EEG abnormalities found 
in the DLB cohort were strongly correlated with CAF scores. This correlation was further 
confirmed in a cohort of MCI subjects converting to DLB. [29] 
In the present study CAF scores were available only in a minority of patients (supplementary table 
1). 
An alternative explanation is that DLB diagnoses were based on clinical features, with no 
neuropathological confirmation. Our DLB patients were strictly evaluated for the presence of 
distinctive features (which if not sensitive are however specific), were diagnosed and followed at 
tertiary centers, and most of the patients had a positive (123) I-FP CIT SPECT scan to support 
diagnosis. However, the criteria for clinical diagnosis of DLB have low sensitivity [1], indicating 
that the diagnosis is often missed especially in the early stages when the frequency of patients 
presenting core symptoms is low.  
Even DAT SPECT, which has high sensitivity and specificity for DLB vs. AD diagnosis, presents a 
percentage of false negative cases [30] and can be positive in other dementia than DLB, such as 
frontotemporal dementia. [31]  
Therefore it is possible that a small percentage of clinically diagnosed AD patients showing an EEG 
pattern typical of DLB were actually DLB.  
There is a small percentage of cases with clinical features of DLB who show a normal striatal 
captation at (123) I-FP-CIT SPECT scan. It has been suggested that some of these patients may not 
have involvement of dopaminergic neurons in the substantia nigra, at least in the earliest stages. 
[32]  
Some DLB patients indeed never develop parkinsonism [33] and in some cases, Lewy-body 
pathology does not follow the Braak pathway of deposition and can be found in the cortex and 
higher brain stem, but at a lesser extent in the lower brain stem. [34-35] 
We suggest that EEG could be especially useful to diagnose DLB in those patients with early 
cortical involvement and relative sparing of substantia nigra. 
An alternative explanation could be that our AD patients were older and more cognitively impaired 
as compared to DLB, thus likely to show signs of EEG rhythm disruption, as also shown in our 
previous study where differences of EEG parameters between DLB and AD patients at two-year 
follow-up were blurred. [21] 
Other methodological limitations need to be discussed:  
The first methodological issue to account for is inherent to the study design. The present is a 
retrospective study on a multicenter cohort of DLB patients who were recruited and followed for 
many different reasons than performing an EEG study. Therefore, we did not exclude patients who 
were under pharmacological treatments at the time of EEG recordings. The absence of perfect 
harmonization of EEG acquisition, including drug withdrawal before EEG recording (which was 
only performed in one center) might have obscured some of the differences between DLB and AD 
patients.   
However, the aim of the study was to test the robustness of the methods in a real-life setting, thus 
we believe that this limitation actually strengthens the findings.  
A confirmation of the validity of the EEG analysis comes also from the correspondence between 
results from the total sample (table 2 and 3) and results obtained in the comparison of EEG from the 
DLB sample with EEG from a numerically equal subgroup of AD patients matched with DLB 
patients for age, sex, education, MMSE and NPI scores (supplementary table 8 and 9). 
Data on pharmacological treatment were not fully available. This might have partially influenced 
the findings. However, since most DLB and AD patients were on cholinesterase inhibitor treatment 
and especially because cholinesterase inhibitors have been shown to reduce both fluctuating 
cognition and EEG abnormalities, [36] it is likely again that, if there was an influence on the results, 
it was toward a more conservative estimate, causing a reduction of both sensitivity and specificity. 
This hypothesis was confirmed by the comparison between patients who underwent drug 
withdrawal vs. patients who did not (supplementary table 6). 
Furthermore, the EEG abnormalities are dynamic (across time) and showed spatial differences 
across the scalp, with prominent abnormalities in posterior derivations (table 2 and supplementary 
table 2), thus unlikely to be fully explained by pharmacological treatments, which would have 
probably smoothened inter-regional differences. 
We therefore believe that also this limitation strengthens the findings, since our results likely 
represent a conservative estimate. It is possible that higher accuracy could be achieved with 
harmonized clinical and EEG procedures. 
We would like to highlight the presence of a specific fast theta band, which we named as pre-alpha 
in the DLB group. This band was deemed to be especially specific for DLB diagnosis in the 
previous EEG cohort study [21] and this finding was further confirmed in this multi-centre study. 
A possible pathophysiological explanation of the peculiar appearance of a dominant fast theta 
rhythm in DLB patients relies on the role of thalamic neurons, in the genesis of different oscillatory 
states, including transitions during the normal sleep–wake cycle and acute cognitive enhancements 
such as improved working-memory and sustained attention. [37] 
There are some situations, such as deafferentation syndromes, where a set of neurons in the 
thalamus displays low rhythmicity in a fast theta band in an otherwise awake brain state. 
In such cases, a dysrhythmic state in a portion of the thalamocortical system is trapped in spindle-
like activity, whereas the rest of the system remains in the usual waking state. [38] There is 
therefore a close relationship among specific thalamic neurons activity, their associated rhythms, 
and different states of consciousness. 
Interestingly, DLB patients present with specific symptoms characterized by clouding of 
consciousness (fluctuating cognition) [1], sleep disturbances (mind-body dissociation), visual 
hallucinations (within-mind dissociation), [39] which have all being demonstrated to be associated 
with abnormalities of thalamic nuclei or thalamo-cortical connectivity. [40-41] 
The presence of fast theta (pre-alpha) rhythm is thought to be generated in the medial pulvinar 
nuclei, which are connected with the parieto-occipital cortex, the very same regions both involved 
in the genesis of specific clinical symptoms, e.g. visual hallucinations [42], and showing the 
presence of specific abnormal EEG rhythms, thus confirming an important role of dysfunctions of 
thalamo-cortical connections in the genesis of DLB clinical features. 
In conclusion our study supports EEG as a helpful tool in the diagnosis of DLB [1] and fosters a 
large prospective multicenter trial to conclusively define the sensitivity and specificity of the 
method and to possibly standardize the method of EEG recording and analysis across centers. 
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Table 1 Demographic and clinical characteristics (mean ± S.E.) of the total samples. 
 
  DLB (n=79) AD (n=133) p value 
AGE 75 ± 1  78 ± 1 0.005 
MALE GENDER (%) 66 37 0.01 
EDUCATION 10 ± 1 8 ± 0 n.s. 
MMSE 22.9 ± 0.5 22.7 ± 0.2 n.s. 
NPI-total 9 ± 1 6 ± 2 n.s. 
UPDRS-III 18 ± 1 2 ± 0 0.00001 
 
MMSE= Mini Mental State Examination; NPI= Neuropsychiatric Inventory; 
UPDRS-III=Unified Parkinson’s Disease Rating Scale-III 
  
Table 2 EEG variables (mean ± st.err.) and statistical results in the comparison between AD and 
DLB in anterior, temporal and posterior derivations. 
 
 
EEG= electroencephalogram; DLB= Dementia with Lewy Bodies; AD= Alzeimer’s Disease; 
DF= Dominant Frequency; DFV= DF variability; FP= Frequency Prevalence. 
EEG variables DLB AD Statistical results           
    (n=79)         (n=133) 
       
 Anterior derivations  
DF 5.9 ± 0.2 7.3 ± 0.2 F(1,210)= 19.8 p<10-4 
DFV 1.4 ± 0.2 1.5 ± 0.2 F(1,210)=0.1 n.s. 
FP delta 24 ± 1 19 ± 1 
F(3,630)=47.0 
n.s. 
FP theta 16 ± 1 10  ± 1 n.s. 
FP pre-alpha 45 ± 2 28 ± 2 p<10-9 
FP alpha 15 ± 2 42 ± 2 p<10-9 
 Temporal derivations 
DF 6.7 ± 0.1 8.3 ± 0.1 F(1,210)=55.9 p<10-6 
DFV 0.7 ± 0.1 0.7 ± 0.1 F(1,210)=0.0 n.s 
FP delta 11 ± 1 9 ± 1 
F(3,630)=69.98 
n.s 
FP theta 11 ± 1 7 ± 1 n.s 
FP pre-alpha 59 ± 2 33 ± 2 p<10-12 
FP alpha 19 ± 2 52 ± 2 p<10-12 
             Posterior derivations 
DF 6.9 ± 0.1 8.7 ± 0.1 F(1,210)=71.5 p<10
-6 
DFV 0.7 ± 0.1 0.4 ± 0.1 F(1,210)=4.0 p<0.05 
FP delta 11 ± 1 7 ± 1 
F(3,630)=85.8 
n.s 
FP theta 13 ±1 7 ± 1 n.s 
FP pre-alpha 54 ± 2 27 ± 2 p<10
-12 
FP alpha 22 ± 3 60 ± 2 p<10
-12 
  
 
 
 
 
Table 3 Cut-off values provided by ROC analysis in all derivations, together with sensitivity 
(Sens), specificity (Spec), positive predictive value (PPV) and negative predictive value (NPV) for 
each EEG variable for the comparison between DLB and AD groups. 
 
Cut-off values    Sens     Spec         PPV       NPV 
Anterior derivations    
DF< 7.3 Hz    84%     59%          55%        86% 
DFV>1.3    42%     66%          42%        66% 
FP pre-alpha>29.4%    84%     61%          56%        86% 
FP alpha<27.6%    86%     65%          60%        89% 
CSA pattern>2    97%     41%          49%        96% 
Temporal derivations         
DF< 7.8 Hz    89%      62%         58%        90%       
DFV>3.3Hz    9%      95%         50%        64%       
FP pre-alpha>36.8Hz    86%      63%         58%        88%       
FP alpha<27.9%    76%      80%         69%        85%       
CSA pattern>2    71%      79%         67%        82%       
Posterior derivations       
DF< 7.8 Hz    80%      72%         63%       86%       
DFV>2.2 Hz     9%      97%         64%       64%       
FP pre-alpha> 32.7%    85%      68%         61%       88%       
FP alpha< 40.7%    82%      77%         68%       88%       
CSA pattern >2    67%      83%         71%       81%       
 
DF= Dominant Frequency; DFV= DF variability; FP= frequency prevalence; CSA= Compressed 
Spectral Array 
 
 
 
Figure 1 
 
Figure 2 
 
Figure legends 
 
Fig. 1 Frequency Prevalence for delta, theta, pre-alpha and alpha bands from anterior, temporal and 
posterior derivations in DLB and AD groups. Significant differences between the two groups were 
found for pre-alpha and alpha band (*). 
 
Fig. 2 ROC curves for dominant frequency (DF), dominant frequency variability (DFV), frequency 
prevalence (FP) in the pre-alpha and alpha bands from anterior, temporal and posterior derivations. 
Accuracy of each EEG variable to separate DLB from AD groups is measured by the area under 
each ROC curve.  Area Under Curve (AUC) values shown in the inset highlight that the best EEG 
discriminating variable is FP in the alpha band (AUC=0.808, 0.831 and 0.844 for anterior, temporal 
and posterior derivation respectively).      
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Supplementary figure 1 
 
 
 
ROC curves for dominant frequency (DF), dominant frequency variability (DFV), frequency 
prevalence (FP) in the pre-alpha and alpha bands from anterior, temporal and posterior derivations. 
Accuracy of each EEG variable to separate 36 DLB patients with positive FP-BETA CIT scan from 
AD patient is measured by the area under each ROC curve. Area Under Curve (AUC) values shown 
in the inset highlight that the best EEG discriminating variable is FP in the alpha band 
(AUC=0.828, 0.852 and 0.873 for anterior, temporal and posterior derivation respectively).      
 
 Supplementary Table 1  
Demographic and clinical characteristics (mean ± S.E.) of each center separately. 
 
Clinical Neurology 
(Italy) 
University Medical 
Centre (Slovenia) 
Campus for Ageing 
and Vitality (UK) 
Karolinska Univ. 
Hospital (Sweden) 
  
DLB 
(n=16) 
AD 
(n=110) 
DLB 
(n=7) 
AD 
(n=0) 
DLB 
(n=23) 
AD 
(n=23) 
DLB 
 (n=33) 
AD 
(n=0) 
AGE 74 ± 1 78 ± 1 75 ± 2 - 76 ± 1 76 ± 2 73 ± 2 - 
MALE 
GENDER (%) 
50% 30% 71% - 78% 70% 63% - 
EDUCATION 8 ± 1 8 ± 0 12 ± 2  - 10 ± 1 11 ± 0 - - 
MMSE 24.1 ± 0.7 23.2 ± 0.2 20.0 ± 0.9 - 23.1 ± 0.8 20.0 ± 0.9 23.0 ± 0.9 - 
NPI-total - - - - 9 ± 1 6 ± 1 - - 
CAF - - - - 3 ± 1 0 ± 0 - - 
ODFA - - - - 2 ± 1 2 ± 1 - - 
UPDRS-III 17 ± 2  - 27 ± 2 - 16 ± 2 2 ± 0 - - 
RBD  
(present %) 
44% - 86% - 50% 5% 80% - 
MMSE= Mini Mental State Examination; NPI= Neuropsychiatric Inventory; CAF= Clinician 
Assessment of Fluctuations; ODFA= One-Day Assessment of Fluctuations; UPDRS-III= Unified 
Parkinson’s Disease Rating Scale-III; RBD= REM sleep Behaviour Disorder. 
   
Supplementary Table 2  
EEG variables (mean ± S.E.) in all derivations and statistical results in the comparison between the previous 
(Bonanni et al., 2008) and the present study. 
 DLB AD 
Variables 
Bonanni  
et al 
(n=36) 
Present 
study 
(n=79) 
Statistical results 
Bonanni 
et al 
 (n=40) 
Present 
study 
(n=133) 
Statistical results 
ANTERIOR DERIVATIONS 
DF 7.0 ± 0.3 5.9 ± 0.2 F(1,113)=9.9 p=0.002 8.0 ± 0.2 7.3 ± 0.2 F(1,171)=2.4 n.s. 
DFV 2.8 ± 0.3 1.4 ± 0.2 F(1,113)=18.5 p=4*10-4 1.7 ± 0.2 1.5 ± 0.2 F(1,171)=0.2 n.s. 
FP delta 10 ± 1 24 ± 1 
F(3,339)=16.6 
p=10-6 8 ± 1 19 ± 1 
F(3,513)=35.4 
p=0.008 
FP theta 8 ± 1 16 ± 1 p=0.05 13 ± 1 10  ± 1 n.s. 
FP pre-alpha 53 ± 2 45 ± 2 p=0.03 8 ± 1 28 ± 2 p<10-9 
FP alpha 25 ± 2 15 ± 2 p=0.004 69 ± 1 42 ± 2 p<10-9 
CSA Pattern         
1 0.0% 2.5%   75.0% 40.6%   
2 25.0% 15.2%   10.0% 24.1%   
3 36.1% 35.4%   0.0% 10.5%   
4 27.8% 41.8%   10.0% 18.0%   
5 11.1% 5.1%   5.0% 6.8%   
TEMPORAL DERIVATIONS 
DF 6.8 ± 0.3 6.7 ± 0.1 F(1,113)=0.04 n.s. 8.0 ± 0.1 8.3 ± 0.1 F(1,171)=1.0 n.s. 
DFV 1.9 ± 0.2 0.7 ± 0.1 F(1,113)=23.0 p=10-5 1.3 ± 0.1 0.7 ± 0.1 F(1,171)=8.2 p=0.005 
FP delta 9 ± 1 11 ± 1 
F(3,339)=1.8 
n.s. 8 ± 1 9 ± 1 
F(3,513)=26.3 
n.s. 
FP theta 8 ± 1 11 ± 1 n.s. 13 ± 1 7 ± 1 n.s. 
FP pre-alpha 54 ± 1 59 ± 2 n.s. 8 ± 1 33 ± 2 p<10-9 
FP alpha 24 ± 1 19 ± 2 n.s. 69 ± 1 52 ± 2 p<10-6 
CSA Pattern         
1 0.0% 3.8%   80.0% 44.4%   
2 25.0% 25.3%   5.0% 34.6%   
3 33.3% 60.8%   5.0% 17.3%   
4 30.6% 10.1%   5.0% 3.0%   
5 11.1% 0.0%   5.0% 0.7%   
POSTERIOR DERIVATIONS 
DF 7.4 ± 0.3 6.9 ± 0.1 F(1,113)=3.5 n.s. 8.3 ± 0.1 8.7 ± 0.1 F(1,171)=1.6 n.s. 
DFV 1.8 ± 0.2 0.7 ± 0.1 F(1,113)=24.3 p=3*10-6 1.1 ± 0.1 0.4 ± 0.1 F(1,171)=22.9 p=4*10-6 
FP delta 7 ± 1 11 ± 1 F(3,339)=2.8 n.s. 6 ± 0 7 ± 1 F(3,513)=17.9 n.s. 
FP theta 10 ± 1 13 ±1  n.s. 11 ± 1 7 ± 1  n.s. 
FP pre-alpha 61 ± 1 54 ± 2  n.s. 6 ± 1 27 ± 2  p<10-9 
FP alpha 19 ± 1 22 ± 3  n.s. 74 ± 1 60 ± 2  p=9*10-5 
CSA Pattern         
1 0 11.4%   100.0% 59.4%   
2 33.3% 21.5%   0.0% 24.1%   
3 25.0% 50.6%   0.0% 13.5%   
4 30.6% 16.5%   0.0% 3.0%   
5 11.1% 0.0%   0.0% 0.0%   
DLB= Dementia with Lewy Bodies; AD= Alzheimer’s Disase; DF= Dominant frequency; DFV= 
DF variability; FP= Frequency Prevalence; CSA= Compressed Spectral Array. 
  
Supplementary Table 3 Sensitivity (Sens), specificity (Spec), positive predictive value (PPV) and 
negative predictive value (NPV) of EEG variables with cut-off values reported in the previous paper 
(Bonanni et al., 2008). 
     
DF= Dominant Frequency; DFV= DF variabilità; FP= Frequency Prevalence; CSA= Compressed 
Spectral Array 
 
 
Bonanni et al. Anterior derivations Temporal derivations 
 
   Posterior derivations 
cut-off Sens Spec  PPV  NPV   Sens Spec  PPV  NPV   Sens Spec    PPV   NPV 
DF<8Hz 91% 49%   51%  90% 89% 62%  58%  90%      80%  72%    63%   86% 
DFV>1.2Hz 42% 66%   42%  66% 19% 83%  39%  63%      22% 89%   53%   66% 
FP pre-alpha>40% 53% 75%   56%  73% 80% 66%  58%  85%     70% 75%   63%   81% 
FP alpha<32% 87% 62%   58%  89% 80% 74%  64%  86%  71% 82%   70%   83% 
CSA pattern>1 97% 41%   49%  96% 96% 44%  51%  95%   89% 59%   56%    90% 
Supplementary Table 4  
EEG variables (mean ± S.E.) and statistical results in the comparison between AD and 36 DLB 
patients with positive (123)I-FP-CIT SPECT  scan. 
 
 
 
 
 
 
 
 
 
 
 
 
(123)I-FP-CIT SPECT = (123)I-FP-CIT Single photon emission computed tomography; 
EEG= electroencephalogram; DLB= Dementia with Lewy Bodies; AD= Alzheimer’s Disease; 
DF= Dominant Frequency; DFV= DF variability; FP= Frequency Prevalence. 
EEG variables DLB AD           Statistical results      
 
   (n=36)         (n=133) 
Anterior derivations 
DF 5.4 ± 0.3 7.3 ± 0.2 F(1,167)=17.4  p<10-3 
DFV 1.4 ± 0.3 1.5 ± 0.2 F(1,167)=0.04 n.s. 
FP delta 26 ± 2 19 ± 1 
F(3,501)=26.0 
n.s. 
FP theta 19 ± 2 10 ± 1 n.s. 
FP pre-alpha 42 ± 3 28 ± 2 p<0.005 
FP alpha 14 ± 3 42 ± 2 p<10-12 
 Temporal derivations 
DF 6.6 ± 0.2 8.3 ± 0.1 F(1,167)=34.8 p<10-6 
DFV 0.8 ± 0.2 0.7 ± 0.1 F(1,167)=0.1 n.s. 
FP delta 13 ± 2 9 ± 1 
F(3,501)=38.8 
n.s 
FP theta 14 ± 2 7 ± 1 n.s 
FP pre-alpha 57 ± 3 33 ± 2 p<10-9 
FP alpha 17 ± 3 52 ± 2 p<10-12 
 Posterior derivations 
DF 6.8 ± 0.2 8.7 ± 0.1 F(1,167)=39.8 p<10-6 
DFV 0.9 ± 0.2 0.4 ± 0.1 F(1,167)=8.3 p<0.005 
FP delta 13 ± 2 7 ± 1 
F(3,501)=50.3 
n.s 
FP theta 16 ± 2 7 ± 1 n.s 
FP pre-alpha 52 ± 3 27 ± 2 p<10-12 
FP alpha 19 ± 4 60 ± 2 p<10-12 
 Supplementary Table 5 Cut-off values provided by ROC analysis in all derivations, together with 
sensitivity (Sens), specificity (Spec), positive predictive value (PPV) and negative predictive value 
(NPV) of each EEG variable for the comparison between 36 DLB patients with positive (123)I-FP-
CIT SPECT scan and AD groups. 
Cut-off values    Sens     Spec         PPV     NPV 
Anterior derivations    
DF< 7.3 Hz    89%     59%         37%       95% 
DFV>2.3    39%     73%         28%       82% 
FP pre-alpha>31.2%    78%     64%         37%       91% 
FP alpha<27.6%    94%     65%         43%       98% 
CSA pattern>2    86%     65%         40%       95% 
Temporal derivations         
DF< 7.3 Hz    81%     75%         47%        93%       
DFV>3.8    11%     95%         40%        80%       
FP pre-alpha>39.8%    81%     65%         39%        93%       
FP alpha<26.4%    81%     80%         53%        94%       
CSA pattern>2    75%     79%         49%        92%       
Posterior derivations       
DF< 7.3 Hz    72%     81%         51%       92%       
DFV>2.3    17%     97%         60%       81%       
FP pre-alpha>25.7%    92%     61%         39%       96%       
FP alpha<48.8%    94%     68%         44%       98%       
CSA pattern>2    67%     83%         52%       90%       
ROC= Receiver Operating Characteristic; DLB= Dementia with Lewy Bodies; AD= Alzheimer’s 
Disease; (123)I-FP-CIT SPECT = (123)I-FP-CIT Single photon emission computed tomography; 
EEG= electroencephalogram; DF= Dominant Frequency; DFV= DF variability; FP= Frequency 
Prevalence; CSA= Compressed Spectral Array. 
 
 
Supplementary Table 6  
EEG variables (mean ± st.err.) and results of the statistical comparisons between AD patients with 
and without drug treatment withdrawal before EEG. 
EEG variables Drug-on 
(n=23) 
Drug-off 
(n=110) 
Statistical results 
DF posterior 7.7 ± 0.4 8.9 ± 0.1 F(1, 131)=10.6 p=0.001 
DF anterior 4.5 ± 0.5 7.9 ± 0.2 F(1,131)=46.4 p<10-4 
DF temporal 7.5 ± 0.4 8.5 ± 0.1 F(1,131)=6.9 p=0.01 
DFV anterior 2.7 ± 0.5 1.3 ± 0.2 F(1,131)=8.2 p=0.005 
FP alpha 
posterior 
38.2 ± 5.5 64.0 ± 2.5 F(3, 393)=13.3 p<10-7 
FP delta 
anterior 
39.7 ± 2.2 14.6 ± 1.1 
F(3,393)=33.5 
p<10-8 
FP alpha 
anterior 
14.2 ± 2.5 48.4 ± 2.4 p<10-12 
FP alpha 
temporal 
32.1 ± 5.0 55.7 ± 2.4 F(3,393)=10.6 p<10-7 
CSA pattern 
posterior 
2 1 F(1, 131)=14.4 p=0.001 
CSA pattern 
anterior 
4 2 F(1,131)=72.3 p<10-4 
CSA pattern 3 2 F(1,131)=18.0 p<10-4 
temporal 
EEG= Electroencephalogram; DF= Dominant Frequency; DFV= DF variability; FP= 
Frequency Prevalence; CSA= Compressed Spectral Array. 
 
 
 
Supplementary Table 7 Demographic and clinical characteristics (mean ± S.E.) of the subgroups 
matched for age, sex, education, MMSE and NPI-total. 
 
  DLB (n=79) AD (n=79) p value 
AGE 75 ± 1  75 ± 1 n.s. 
MALE GENDER (%) 66 66 n.s. 
EDUCATION 10 ± 1 9 ± 1 n.s. 
MMSE 22.9 ± 0.5 22.7 ± 0.3 n.s. 
NPI-total 9 ± 1 6 ± 1 n.s. 
UPDRS-III 18 ± 1 2 ± 0 0.00001 
 
MMSE= Mini Mental State Examination; NPI= Neuropsychiatric Inventory; UPDRS-III=Unified 
Parkinson’s Disease Rating Scale-III 
 
 
Supplementary Table 8 EEG variables (mean±st.err.) and statistical results in the comparison 
between DLB and AD subgroup in anterior, temporal and posterior derivations. 
 
EEG variables DLB AD Statistical results           
    (n=79)         (n=79)        
 Anterior derivations  
DF 5.9 ± 0.2 7.0 ± 0.3 F(1,156)= 9.9 p<0.002 
DFV 1.4 ± 0.2 1.5 ± 0.2 F(1,156)=0.1 n.s. 
FP delta 24 ± 1 21 ± 2 
F(3,468)=31.7 
n.s. 
FP theta 16 ± 1 12  ± 1 n.s. 
FP pre-alpha 45 ± 2 28 ± 2 p<10-9 
FP alpha 15 ± 2 39 ± 3 p<10-9 
 Temporal derivations 
DF 6.7 ± 0.1 8.3 ± 0.2 F(1,156)=49.0 p<10-6 
DFV 0.7 ± 0.1 0.7 ± 0.2 F(1,210)=0.0 n.s 
FP delta 11 ± 1 9 ± 1 
F(3,468)=51.3 
n.s 
FP theta 11 ± 1 7 ± 1 n.s 
FP pre-alpha 59 ± 2 34 ± 3 p<10-12 
FP alpha 19 ± 2 49 ± 3 p<10-12 
             Posterior derivations 
DF 6.9 ± 0.1 8.5 ± 0.2 F(1,156)=47.9 p<10-6 
DFV 0.7 ± 0.1 0.3 ± 0.1 F(1,156)=5.6 p<0.02 
FP delta 11 ± 1 8 ± 1 
F(3,468)=61.0 
n.s 
FP theta 13 ±1 7 ± 1 n.s 
FP pre-alpha 54 ± 2 27 ± 3 p<10-12 
  
EEG= electroencephalogram; DLB= Dementia with Lewy Bodies; AD= Alzeimer’s Disease; 
DF= Dominant Frequency; DFV= DF variability; FP= Frequency Prevalence; 
 
 
 
 
Supplementary Table 9 Cut-off values provided by ROC analysis in all derivations, together with 
sensitivity (Sens), specificity (Spec), positive predictive value (PPV), negative predictive value 
(NPV) and area under the curve (AUC) for each EEG variable in the comparison between DLB 
(n=79) and AD subgroup (n=79). 
 
Cut-off values    Sens     Spec         PPV       NPV   AUC 
Anterior derivations       
DF< 7.3 Hz    84%     56%          65%        77% 0.675 
DFV>2.3    34%     72%          55%        52% 0.529 
FP pre-alpha>29.4%    84%     63%          69%        79% 0.768 
FP alpha<30.2%    87%     57%          67%        82% 0.773 
CSA pattern>2    82%     54%          64%        75% 0.670 
Temporal derivations          
FP alpha 22 ± 3 57 ± 3 p<10-12 
DF< 7.3 Hz    75%      76%         76%        75% 0.805       
DFV>3.3Hz    9%      95%         64%        51% 0.487       
FP pre-alpha>35.6Hz    87%      62%         70%        83% 0.785       
FP alpha<26.9%    75%      77%         77%        75% 0.811       
CSA pattern>2    71%      75%         74%        72% 0.762       
Posterior derivations        
DF< 7.8 Hz    80%      68%         72%       77% 0.783       
DFV>2.3 Hz     9%      99%         88%       52% 0.580       
FP pre-alpha> 31.6%    86%      68%         73%       83% 0.809       
FP alpha< 40.7%    82%      75%         76%       81% 0.829       
CSA pattern >1    89%      62%         70%       84% 0.799       
 
DF= Dominant Frequency; DFV= DF variability; FP= frequency prevalence; CSA= Compressed 
Spectral Array 
 
